INT288526

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 2009
Last Reported 2009
Negated 0
Speculated 1
Reported most in Body
Documents 1
Total Number 10
Disease Relevance 8.59
Pain Relevance 9.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Gch1) nucleolus (Gch1) nucleus (Gch1)
protein complex assembly (Gch1) protein complex (Gch1) cytoplasm (Gch1)
Anatomy Link Frequency
sciatic nerve 1
Gch1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
GCH1 560 100.00 Very High Very High Very High
Potency 10 99.92 Very High Very High Very High
dorsal root ganglion 160 99.84 Very High Very High Very High
Neuropathic pain 140 99.64 Very High Very High Very High
Pain 460 98.40 Very High Very High Very High
Inflammation 100 98.08 Very High Very High Very High
Sciatic nerve 150 98.00 Very High Very High Very High
Lasting pain 10 97.76 Very High Very High Very High
Spinal cord 60 96.48 Very High Very High Very High
Dorsal horn 40 95.08 Very High Very High Very High
Disease Link Frequency Relevance Heat
Ganglion Cysts 160 99.84 Very High Very High Very High
Neuropathic Pain 170 99.64 Very High Very High Very High
Nervous System Injury 130 99.36 Very High Very High Very High
Pain 520 98.40 Very High Very High Very High
INFLAMMATION 100 98.08 Very High Very High Very High
Hypersensitivity 10 83.76 Quite High
Dystonia 10 74.36 Quite High
Inborn Genetic Diseases 10 73.00 Quite High
Neurodegenerative Disease 20 57.52 Quite High
Toxicity 10 54.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
To determine whether GCH1 downregulation affects microglial activation, we performed immunohistochemistry with the Iba-1 antibody, a microglial marker (Fig. 8).
Spec (whether) Negative_regulation (downregulation) of GCH1 associated with gch1
1) Confidence 0.54 Published 2009 Journal Mol Pain Section Body Doc Link PMC2785765 Disease Relevance 1.02 Pain Relevance 1.07
Therefore, the data suggests that GCH1 levels can be reduced by introducing rAAV-shGCH1, leading to pain relief.
Negative_regulation (reduced) of GCH1 associated with pain and gch1
2) Confidence 0.40 Published 2009 Journal Mol Pain Section Abstract Doc Link PMC2785765 Disease Relevance 0.64 Pain Relevance 0.97
We have confirmed the therapeutic potential of shRNA-induced GCH1 down-regulation via rAAV in neuropathic pain treatment using the sciatic nerve as a delivery route.
Negative_regulation (regulation) of GCH1 in sciatic nerve associated with neuropathic pain, gch1 and sciatic nerve
3) Confidence 0.40 Published 2009 Journal Mol Pain Section Body Doc Link PMC2785765 Disease Relevance 0.26 Pain Relevance 0.47
The present study provides clear evidence of the therapeutic potency of GCH1 down-regulation in DRG via rAAV-shGCH1-mediated silencing for treating neuropathic pain.
Negative_regulation (down) of GCH1 associated with dorsal root ganglion, neuropathic pain, gch1 and potency
4) Confidence 0.40 Published 2009 Journal Mol Pain Section Body Doc Link PMC2785765 Disease Relevance 1.17 Pain Relevance 1.29
Certain small molecules, such as the GCH1 inhibitor, 2-4-diamino-6-hydroxypyrimidien (DAHP), have been found to rapidly ameliorate pain symptoms in animal models [10].
Negative_regulation (inhibitor) of GCH1 associated with pain and gch1
5) Confidence 0.40 Published 2009 Journal Mol Pain Section Body Doc Link PMC2785765 Disease Relevance 0.98 Pain Relevance 1.14
These results suggest that GCH1 down-regulation is a promising strategy to treat neuropathic pain with minimal side-effects, which subsequently suggests the importance of developing an effective gene silencing system.
Negative_regulation (regulation) of GCH1 associated with neuropathic pain and gch1
6) Confidence 0.40 Published 2009 Journal Mol Pain Section Body Doc Link PMC2785765 Disease Relevance 0.67 Pain Relevance 0.95
Attenuation of neuropathic pain behavior through downregulation of GCH1 levels via rAAV-shGCH1
Negative_regulation (downregulation) of GCH1 associated with gch1 and neuropathic pain
7) Confidence 0.40 Published 2009 Journal Mol Pain Section Body Doc Link PMC2785765 Disease Relevance 1.10 Pain Relevance 0.88
The present study provides clear evidence of the therapeutic potency of GCH1 down-regulation in DRG via rAAV-shGCH1-mediated silencing for treating neuropathic pain.
Negative_regulation (regulation) of GCH1 associated with dorsal root ganglion, neuropathic pain, gch1 and potency
8) Confidence 0.40 Published 2009 Journal Mol Pain Section Body Doc Link PMC2785765 Disease Relevance 1.17 Pain Relevance 1.29
Accordingly, we propose that suppression of GCH1 using rAAV is a promising gene-based strategy to treat chronic pain.


Negative_regulation (suppression) of GCH1 associated with lasting pain and gch1
9) Confidence 0.40 Published 2009 Journal Mol Pain Section Body Doc Link PMC2785765 Disease Relevance 0.47 Pain Relevance 0.65
Attenuation of neuropathic pain behavior through downregulation of GCH1 levels via rAAV-shGCH1
Negative_regulation (downregulation) of shGCH1 associated with gch1 and neuropathic pain
10) Confidence 0.35 Published 2009 Journal Mol Pain Section Body Doc Link PMC2785765 Disease Relevance 1.11 Pain Relevance 0.89

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox